Taiho Entered into an Agreement to Acquire Cullinan for CLN-081/TAS6417 to Treat EGFR Exon20 Non-Small Cell Lung Cancer
Shots:
- Cullinan to receive $275M up front, ~ $130M in regulatory-based milestones & the transaction is expected to close in Q2’22. Additionally, both companies will equally share 50% of the profits for the future clinical development of CLN-081/TAS6417 in the US
- Under the agreement with Taiho, Cullinan gets global rights to CLN-081/TAS6417 outside Japan & obtains the option to co-commercialize & co-develop CLN-081/TAS6417 (TK inhibitor)
- Taiho retains exclusive rights globally to CLN-081/TAS6417 in territories outside US & China. CLN-081/TAS6417 is being studied in the P-I/IIa study for NSCLC with exon 20 insertion mutation with an expected initiation of the study in H2’22
Ref: Globenewswire | Image: Taiho
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
